J&J flexes $15B quarter for innovative drugs as biosimilars chip away at Stelara

Johnson & Johnson reported robust second-quarter results, with total sales reaching $23.7 billion, a nearly 6% increase, driven by record innovative medicines sales exceeding $15 billion. This performance successfully offset a significant 43% decline in Stelara sales to $1.7 billion, demonstrating J&J's effective navigation of the patent cliff. Strong growth in oncology, led by Darzalex and new launches, and immunology with Tremfya, underpinned the results, leading the company to raise its full-year sales guidance to $92.7-$93.1 billion and reiterate its ambition to become the top oncology company by 2030.

Analysis

Johnson & Johnson's second-quarter results demonstrate a successful navigation of the Stelara patent cliff, a key investor concern heading into 2025. The company posted a nearly 6% year-over-year increase in total sales to $23.7 billion, driven by a record performance in its Innovative Medicines division, which surpassed $15 billion in quarterly sales for the first time. This robust growth effectively offset a significant 43% decline in Stelara revenue, which fell by over $1.2 billion to $1.7 billion. The performance was underpinned by substantial, double-digit growth from 13 brands, prominently in oncology with Darzalex sales rising 23% to $3.5 billion and Erleada growing 23% to $908 million. In immunology, Tremfya is emerging as a strong successor to Stelara, with sales growing 31% to $1.2 billion following recent FDA approvals. This execution prompted management to raise full-year sales guidance by $2 billion to a range of $92.7 billion to $93.1 billion and reiterate its strategic goal of becoming the top oncology company by 2030. Furthermore, management highlighted favorable new legislation providing permanent expensing for domestic R&D and capital investments, suggesting a supportive environment for its planned $55 billion U.S. investment.

Key Decisions for Investors

• Investors should view these results as a significant de-risking event, as the company has proven its diversified portfolio can more than compensate for the revenue erosion from its former blockbuster, Stelara.
• Attention should now pivot to tracking the sales momentum of key growth drivers, particularly the oncology portfolio including Darzalex and Carvykti, and the uptake of Tremfya in new immunology indications, as these are critical to achieving the newly raised guidance.
• The combination of a strong product cycle and supportive tax legislation for domestic R&D and capital expenditures warrants a positive adjustment to long-term growth and margin assumptions, particularly concerning the company's ambitious 2030 oncology sales target.